Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study.
Elena M Yubero-SerranoJuan F Alcalá-DiazFrancisco M Gutierrez-MariscalAntonio P Arenas-de LarrivaPatricia J Peña-OrihuelaRuth Blanco-RojoJavier Martinez-BotasJose D Torres-PeñaPablo Perez-MartinezJose M OrdovasJavier Delgado-ListaDiego Gómez-CoronadoJose Lopez-MirandaPublished in: Cardiovascular diabetology (2021)
Our findings suggest an inverse relationship between CEC and PAD in CHD patients. These results support the importance of identifying underlying mechanisms of PAD, in the context of secondary prevention, that provide potential therapeutic targets, that is the case of CEC, and establishing strategies to prevent or reduce the high risk of cardiovascular events of these patients. Trial registration https://clinicaltrials.gov/ct2/show/NCT00924937 . Unique Identifier: NCT00924937.
Keyphrases
- end stage renal disease
- cardiovascular events
- type diabetes
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- coronary artery disease
- clinical trial
- peripheral artery disease
- cardiovascular disease
- prognostic factors
- magnetic resonance imaging
- randomized controlled trial
- magnetic resonance
- patient reported outcomes
- insulin resistance
- skeletal muscle
- image quality